Keyphrases
Corticosteroids
100%
Liver Transplant Recipients
100%
Antibody Induction
100%
T Cells
94%
Specific Antibodies
88%
Confidence Interval
77%
Risk Ratio
72%
Interleukin-2 Receptor Antagonist
22%
Clinical Analysis
16%
Liver Transplantation
16%
Cytomegalovirus Infection
16%
High Risk
11%
Adverse Events
11%
Randomized Trial
11%
Type 1 Diabetes Mellitus (T1DM)
11%
Randomized Clinical Trial
11%
Immunosuppression
11%
Systematic Error
11%
Acute Rejection
11%
Risk of Bias
11%
Random Error
11%
Low Risk
5%
No Significant Difference
5%
Quality of Life
5%
Embase
5%
Meta-analysis
5%
Hepatobiliary
5%
Inclusion Criteria
5%
Mortality Risk
5%
Statistical Analysis
5%
MEDLINE
5%
Cochrane Central Register of Controlled Trials
5%
Treatment Options
5%
Infection Risk
5%
Loss Risk
5%
Pharmaceutical Companies
5%
Immunosuppressive Therapy
5%
World Health Organization
5%
Antithymocyte Globulin
5%
Risk of Malignancy
5%
Number of Trials
5%
Cochrane
5%
Error Bias
5%
Post-transplant Lymphoproliferative Disorder
5%
Subgroup Differences
5%
Number of Participants
5%
Induction Therapy
5%
Science Citation Index Expanded
5%
Hematological Adverse Events
5%
Recurrence Risk Ratio
5%
Liver Failure
5%
Information Size
5%
Sequential Monitoring
5%
Graft Loss
5%
RevMan
5%
International Clinical Trials Registry Platform (ICTRP)
5%
Risk Domain
5%
Dichotomous Data
5%
Continuous Data
5%
Daclizumab
5%
Basiliximab
5%
Hepatitis C Virus Recurrence
5%
Citation Searching
5%
Medicine and Dentistry
Antibodies
100%
T Cell
100%
Liver Graft
100%
Receptor Antagonist
25%
Interleukin 2 Receptor
25%
Adverse Event
18%
Immunosuppressive Treatment
18%
Sequential Analysis
18%
Liver Transplantation
18%
Cytomegalovirus Infection
18%
Diabetes Mellitus
12%
Randomized Clinical Trial
12%
Acute Graft Rejection
12%
Quality of Life
6%
Infection
6%
Meta-Analysis
6%
Recurrence Risk
6%
Clinical Trial
6%
Cancer
6%
Hepatitis C Virus
6%
Group Trial
6%
End Stage Liver Disease
6%
Immunosuppressive Drug
6%
Lymphoproliferative Disease
6%
Thymocyte Antibody
6%
T Lymphocyte Antibody
6%
Graft Failure
6%
Basiliximab
6%
Daclizumab
6%
Immunology and Microbiology
Transplant Procedure
100%
Monospecific Antibody
100%
T Cell
100%
Interleukin 2 Receptor
25%
Liver Transplantation
18%
Cytomegalovirus Infection
18%
Immunosuppression
12%
Acute Graft Rejection
12%
Hepatitis C Virus
6%
Immunosuppressive Therapy
6%
Anti-Thymocyte Globulin
6%
SciSearch
6%
Cochrane Library
6%
Immunosuppressive Drug
6%
T Lymphocyte Antibody
6%
Lymphoproliferative Disorders
6%
Daclizumab
6%
Basiliximab
6%
Pharmacology, Toxicology and Pharmaceutical Science
Antibodies
100%
Receptor Antagonist
25%
Interleukin 2 Receptor
25%
Adverse Event
18%
Cytomegalovirus Infection
18%
Randomized Clinical Trial
12%
Diabetes Mellitus
12%
Immunosuppressive Agent
12%
Acute Graft Rejection
12%
Recurrence Risk
6%
Clinical Trial
6%
Infection
6%
Hepatitis C Virus
6%
Group Trial
6%
Thymocyte Antibody
6%
End Stage Liver Disease
6%
Lymphoproliferative Disease
6%
Graft Failure
6%
Basiliximab
6%
Daclizumab
6%
T Lymphocyte Antibody
6%